홈GEDSF • OTCMKTS
add
Gedeon Richter ADR
시장 뉴스
재무
손익계산서
수익
순이익
(HUF) | 2024년 9월info | 전년대비 변동 |
---|---|---|
수익 | 2167.30억 | 14.95% |
운영비 | 946.86억 | 10.59% |
순이익 | 370.60억 | -32.07% |
순이익률 | 17.10 | -40.89% |
주당 수익 | — | — |
EBITDA | 763.89억 | 23.89% |
유효 세율 | 19.13% | — |
대차대조표
총자산
총부채
(HUF) | 2024년 9월info | 전년대비 변동 |
---|---|---|
현금 및 단기 투자 | 749.87억 | -29.24% |
총자산 | 1.49조 | 9.53% |
총부채 | 2588.34억 | -1.37% |
총자기자본 | 1.23조 | — |
발행 주식 | 1.83억 | — |
주가순자산비율 | 0.00 | — |
총자산이익률 | 10.29% | — |
자본이익률 | 11.59% | — |
현금 흐름
순현금흐름
(HUF) | 2024년 9월info | 전년대비 변동 |
---|---|---|
순이익 | 370.60억 | -32.07% |
영업 현금 흐름 | 675.52억 | 56.30% |
투자 현금 흐름 | -136.88억 | 54.12% |
자금 조달 현금 흐름 | -366.96억 | -409.23% |
순현금흐름 | 171.18억 | -34.71% |
잉여 현금 흐름 | 131.87억 | 1,594.12% |
정보
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.
Gedeon Richter Plc. has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $6.6 billion as of 2018, the third largest of companies with a primary listing on the Budapest Stock Exchange. It has secondary listings on the Luxembourg Stock Exchange.
Richter sells products for the central nervous system, women's health and cardiovascular therapeutic areas among others. The company is also active in biosimilar product development. The company was established in Budapest by Gedeon Richter, a pharmacist, in 1901. Wikipedia
CEO
설립
1901
직원 수
11,603